





UNIVERSITY of LIMERICK
OLLSCOIL LUIMNIGH
STATISTICAL CONSULTING UNIT

Research in Health Sciences

Study Design & Methodology

Dr Jean Saunders C.Stat

Inc extra slides by Declan Lyons MSc FRCP FRCPI MD



Study Design

Influenced by:

Aims

Resources

Ethics

The Scientific Method: A Model for Conducting Scientific Research (Writing the Protocol)

1. **Defining the Question**
2. **Locating Resources/Gathering Information & Materials**
3. **Forming a Hypothesis/Hypotheses**
4. **Planning the Research/Developing Data Collection Methods**
5. **Collecting Data**
6. **Organising & Analysing the Data**
7. **Interpreting the Data & Drawing Conclusions**
8. **Communicating the Results**

Defining the Question:

- ◆ Specifically, what do I want to know?
- ◆ What is the purpose of asking this question?
- ◆ What will the answer tell me?
- ◆ Can this question be answered through research?
- ◆ (Can I describe how I might answer it?)
- ◆ What do I expect to find once I've conducted my research?

Resources/Gathering Information & Materials:

- ◆ What do I know about my topic?
- ◆ What additional information would help me?
- ◆ How can I use different sources of information (experts, books, articles, computer databases) to gather the information I need?
- ◆ Where will I conduct this research?
- ◆ Where are the organisms or events I want to study?
- ◆ What resources are available to me--time, equipment, people, money, facilities, etc.?

Forming a Hypothesis/Hypotheses:

- ◆ What do I expect to find once I've conducted my research?
- ◆ (Keep it simple)

Planning the Research/Developing Data Collection Methods:

- ◆ How will I answer my research question/test my hypotheses?
- ◆ What data do I need to collect?
- ◆ How will I collect these data? What equipment or supplies do I need?
- ◆ Do I have a reference point (control) with which to compare my data?
- ◆ To answer my question, do I need to manipulate variables?
- ◆ How many (samples, sites, tests, etc.) do I need?
- ◆ What record-keeping techniques (e.g. data sheet, journal) will I use? Are my data collection techniques organised and thorough?
- ◆ Are there sequential steps to my research? If so, what are they? How will I plan my time?

Collecting Data:

- ◆ Am I recording all relevant data? Can I read and understand my notes?
- ◆ Am I keeping track of what I did at each step?
- ◆ Am I being objective in my data collection?

Organising & Analysing the Data:

- ◆ How will I organise and summarise the data I've collected?
- ◆ What do my data show?
- ◆ How should I present my data graphically so that others can see the results clearly? (e.g. bar graphs, tables, pie charts, line graphs, etc.)
- ◆ Are the results significant?
- ◆ Are there tests I might use to tell me if the results are significant?

Interpreting the Data & Drawing Conclusions:

- ◆ What alternative hypotheses might explain these results?
- ◆ Am I considering all relevant data, including extremes or "oddball data" in my analysis?
- ◆ How might my sampling or data collection methods have affected these results?
- ◆ What answer do my results provide to my original question?
- ◆ How do my results compare to what I expected to happen (my hypothesis)?
- ◆ What can I conclude from my results?
- ◆ How do my conclusions affect the community or "big picture" (implications)?

Results:

- ❖ Who is my audience? What is the best way to communicate to my audience? (e.g. written report, oral or poster presentation, video, etc.) What visual aids will help my audience clearly understand this research?
- ❖ Have I addressed all of the following components of my research in my communication?:
 - Introduction to question, purpose of this research and why it is interesting or matters
 - Description of methods used to collect data
 - Results
 - Conclusions
 - What questions are raised by my research? How do others respond to my work?

Study Types 1

- ❖ Experimental Design eg. RCT, animal, laboratory
- ❖ Observational eg. cohort, case control

Study Types 2

- **Cross-sectional studies** eg. census, survey, point prevalence
no use for evaluating incidence
- **Longitudinal studies**
prospective or retrospective
- **Repeated Cross sectional**

Study Types 3

Control Group

Bias


systematic difference between the results of a study & the true state of affairs

- Observer
- Confounding
- Selection
- Information
- Publication



Specific Design Elements

- Blocking eg age, sex
- Parallel versus cross - over design

Parallel



Crossover



Factorial Experiment

BETA CAROTENE

Yes

No

ASPIRIN Yes

No

	Yes	● ●	● —
	No	— ●	— —

RCT



Phase 1 Pre Clinical, Dose Finding

Phase 2 Safety, Efficacy

Phase 3 Full evaluation for defined indication

Phase 4 PMS

Endpoints $1^{\circ}, 2^{\circ}$

Randomisation

Stratified randomisation controls for effects of important factors

Blocked randomisation gives roughly equal sized treatment groups

Systematic allocation eg DOB, date of week

Cluster randomisation eg everyone from a particular practice

Blinding

Double

Single

Observer

Ethics committee

Informed consent

Protocol

Inclusion & exclusion criteria

Protocol deviations & intention to treat

Cohort Studies

eg risk factor evaluation

fixed or dynamic

Estimated Relative Risk (1 same risk in exposed and unexposed groups)

MI in subsequent 10 years

Smoker at
baseline

	YES	NO	<u>TOTAL</u>
EVER	563 (9.5%)	5336 (90.5%)	5899
NEVER	87 (4.8%)	1732 (95.2%)	1819
<u>TOTAL</u>	650 (8.4%)	7068 (71.6%)	7718

Estimated Relative Risk

Yes MI in the "Ever Gp"

Total No.in the "Ever Gp"

$$= \frac{(563/5899)}{(87/1819)} = 2.00$$

Yes MI in the "Never Gp"

Total No.in the "Never Gp"

Case - control studies

- Incident cases
- Prevalent cases
- Matching

Odds Ratio

Current use of HRT

Hip Fracture

	YES	NO	<u>TOTAL</u>
EVER	40 (14%)	1287 (30%)	1327
NEVER	239	3023	3262
<u>TOTAL</u>	279	4310	4589

Observed Odds Ratio

Yes fracture in the "HRT Gp"

NO fracture in the "HRT Gp"

$$= (40 \times 3023) / (239 \times 1287)$$

NO fracture in the "NO HRT Gp"

Yes fracture in the "NO HRT Gp"

$$= 0.39$$

A postmenopausal woman who is a current user of HRT had 39% of the risk of hip fracture of a woman who had never used HRT
ie being a current user of HRT reduced the risk of hip fracture by 61%

Pros

Cons

Quick ,cheap & easy	Recall bias
Suitable for rare diseases	Attributing causality
Wide range of RFs ix	Rare risk factors
No loss to follow up	

Causality in Observational studies Hill 1965

Cause must precede effect

Association must be plausible

Results should be consistent from a no. of studies

Cause & effect association should be strong

Dose - response relationship

Removing the factor should reduce risk


Variation (leads to lack of Precision)

- Random
- Biological
- Measurement

Mechanisms to reduce variation

Replication

Sample Size



SAMPLE SIZE & POWER CALCULATION

Why perform sample size calculations?

- We need to know how many people are required to detect a treatment difference should it exist. If a study is too small, it may lack the *power* to pick up differences.
- Clinical trials can be expensive – we don't want to waste time, money and resources on a study that will be unable to pick up clinically relevant differences. We also don't want to study more people than necessary.
- It is unethical to subject patients to treatment unnecessarily – either by performing a trial with low power or by recruiting more patients than necessary.

Errors in hypothesis testing

When testing our null hypothesis, mistakes can be made. There are two types of errors: Type I and Type II.

Type I error: We find a difference and reject the null hypothesis, but in truth no difference exists (false positive).

The probability of such an error is usually noted α is equal to the **significance level** (usually 5%).

→ We therefore accept that we have a 1 in 20 (5%) chance of detecting a false positive.

Type II error: We find no difference and do not reject the null hypothesis, but in truth a difference exists (false negative).

The probability of such an error is noted β and an acceptable level is usually 20 %. The converse of this is that if a true difference were present we would be able to detect it 80% of the time.

The probability of being able to detect a true difference should it exist is also called **power**.

What determines statistical power?


Statistical power is determined by how frequent the outcome of interest is, the amount of variability in your data, the number of people in your sample, and the size of the minimum difference you wish to detect.

Power is low (hard to detect differences when they exist) when:

- there is a great deal of variability in the data (standard deviation is large)
- the sample is small
- small, subtle differences are to be detected

Usually, we set power to a desired level and then design the study in such a way that this level of power is achieved. Most studies seek to have power of 80% - 90%.

Once we have set the desired power of the study, we can estimate how many subjects we would require to be able to detect the **minimum clinically relevant difference** (decided in advance) should it exist. This calculation is the **sample size calculation**.



"84 patients in each group were required to have a 90% chance of detecting a difference in means of 20(mmHg) at the 5% level of significance."

84 patients in each group were required to have a 90% chance of detecting a difference in means of 20(mmHg) at the 5% level of significance."

N

POWER

WHAT IS CLINICALLY RELEV (δ)

SL(α):

We need to know STANDARD DEVIATION (σ)

We calculate the Standardised Difference (δ / σ)

SAMPLE SIZE

QUANTIFY THE FOLLOWING QUANTITIES

- POWER: THE CHANCE OF DETECTING IF A SPECIFIED EFFECT OCCURS 70-80% ($p=0.7 \rightarrow 0.8$ ($1-\beta$))
 $\beta=0.2 \rightarrow 0.3$
- $SL(\alpha)$: THE LEVEL BELOW WHICH THE NULL HYPOTHESIS IS REJECTED 0.05
- VARIABILITY OF OBSERVATIONS: eg STANDARD DEVIATION (σ)
- SMALLEST EFFECT OF INTEREST: WHAT IS CLINICALLY RELEV (δ)
Standardised Difference (δ / σ)

EASY

EASY

HARD

EASY

BP Rx

RCT PARALLEL

- WE WANT A HIGH POWER eg 90%, $1-\beta=0.9$, $\beta=0.1$
- SIGNIFICANCE LEVEL of 0.05
- SBP STANDARD DEV = 40mmHg (previous data)
- WHAT DIFFERENCE IS GOING TO BE CLINICALLY RELEVANT TO US = 20mmHg (ie 1/2 STDEV)

Standardised Difference $(\delta / \sigma) = 20/40 = 0.5 = D_s$

- Altman Power Plot
- Connect the standardised difference to requisite power to get N.

$$N^* \text{ in each group} = f(\alpha, \beta) \times \frac{2 \sigma^2}{(\mu_1 - \mu_2)^2} = f(\alpha, \beta) \times \frac{2}{D_S^2}$$

Where $f(\alpha, \beta) =$

		β			
		0.05	0.1	0.2	0.5
α	0.05	13.0	10.5	7.85	3.84
	0.01	17.8	14.9	11.7	6.63

Therefore for $D_S = 0.5$, $\alpha = 0.05$ and $\beta = 0.1$

$$N = 10.5 \times 2 / (0.5)^2 = 84 \text{ in each group}$$

* Assumes equal numbers in each group. Other formulae exist when this is not the case.

- How do I reduce my sample size?
- Accept lower power & risk type II error
- Reduce the variance eg Crossover study

HOW MANY TESTS IN YOUR STUDY?

- 1 TEST = 1 CALCULATION
- 5 TESTS = 5 CALCULATIONS - TAKE THE LARGEST SAMPLE SIZE

SCU – Contact Details

Dr Jean Saunders
Executive Director
Statistical Consulting Unit
(Office of the Vice President Academic & Registrar)
Department of Mathematics and Statistics
University of Limerick
Tel: +353 - 61 – 213471
Mob: +353 – 86 - 3866353
Fax: +353 - 61 - 334927
email jean.saunders@ul.ie